132 related articles for article (PubMed ID: 32079692)
1. Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
Caracciolo D; Scionti F; Juli G; Altomare E; Golino G; Todoerti K; Grillone K; Riillo C; Arbitrio M; Iannone M; Morelli E; Amodio N; Di Martino MT; Rossi M; Neri A; Tagliaferri P; Tassone P
Haematologica; 2021 Jan; 106(1):185-195. PubMed ID: 32079692
[TBL] [Abstract][Full Text] [Related]
2. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N; Kelley S; Robert C; Baer MR; Perrotti D; Gambacorti-Passerini C; Civin C; Scheibner K; Rassool FV
Mol Cancer Res; 2015 Apr; 13(4):699-712. PubMed ID: 25828893
[TBL] [Abstract][Full Text] [Related]
3. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.
Mansour WY; Borgmann K; Petersen C; Dikomey E; Dahm-Daphi J
DNA Repair (Amst); 2013 Dec; 12(12):1134-42. PubMed ID: 24210699
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.
Herrero AB; San Miguel J; Gutierrez NC
PLoS One; 2015; 10(3):e0121581. PubMed ID: 25790254
[TBL] [Abstract][Full Text] [Related]
5. TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors.
McAvera RM; Morgan JJ; Herrero AB; Mills KI; Crawford LJ
Sci Rep; 2024 Apr; 14(1):8797. PubMed ID: 38627415
[TBL] [Abstract][Full Text] [Related]
6. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
8. Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.
Caracciolo D; Juli G; Riillo C; Coricello A; Vasile F; Pollastri S; Rocca R; Scionti F; Polerà N; Grillone K; Arbitrio M; Staropoli N; Caparello B; Britti D; Loprete G; Costa G; Di Martino MT; Alcaro S; Tagliaferri P; Tassone P
J Transl Med; 2022 Oct; 20(1):482. PubMed ID: 36273153
[TBL] [Abstract][Full Text] [Related]
9. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
10. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
11. Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel.
Caracciolo D; Riillo C; Di Martino MT; Tagliaferri P; Tassone P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808562
[TBL] [Abstract][Full Text] [Related]
12. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
13. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.
Luijsterburg MS; de Krijger I; Wiegant WW; Shah RG; Smeenk G; de Groot AJL; Pines A; Vertegaal ACO; Jacobs JJL; Shah GM; van Attikum H
Mol Cell; 2016 Feb; 61(4):547-562. PubMed ID: 26895424
[TBL] [Abstract][Full Text] [Related]
14. Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining.
Doksani Y; de Lange T
Cell Rep; 2016 Nov; 17(6):1646-1656. PubMed ID: 27806302
[TBL] [Abstract][Full Text] [Related]
15. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
[TBL] [Abstract][Full Text] [Related]
16. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
17. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
Soni A; Siemann M; Pantelias GE; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
[TBL] [Abstract][Full Text] [Related]
18. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
19. Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness.
Richter C; Marquardt S; Li F; Spitschak A; Murr N; Edelhäuser BAH; Iliakis G; Pützer BM; Logotheti S
J Exp Clin Cancer Res; 2019 Jul; 38(1):292. PubMed ID: 31287003
[TBL] [Abstract][Full Text] [Related]
20. miR-22 suppresses DNA ligase III addiction in multiple myeloma.
Caracciolo D; Di Martino MT; Amodio N; Morelli E; Montesano M; Botta C; Scionti F; Talarico D; Altomare E; Gallo Cantafio ME; Zuccalà V; Maltese L; Todoerti K; Rossi M; Arbitrio M; Neri A; Tagliaferri P; Tassone P
Leukemia; 2019 Feb; 33(2):487-498. PubMed ID: 30120376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
